Focus on Optimized Dosing of Ibrutinib Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Peter Clark, MA, MD, FRCP: A Payer Perspective

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Issues in Oncology

The ASCO Post Staff

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Mar

Today In Oncology

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Related Videos

Peter Clark, MA, MD, FRCP: A Payer Perspective

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Stanford Names Leader for Drug Development and Precision Oncology

Neoadjuvant Sacituzumab Govitecan Plus Perioperative Pembrolizumab in Muscle-Invasive Bladder Cancer

Prostate Cancer Does Taking ARPIs and Anticoagulants Together Raise Risks

FDA Releases Updated Guidance on Biosimilar Development

SABCS 2025: High-Level Review of Select Data